Clinical perspectives of bispecific antibodies in cancer G. C. de GastJ. G. J. van de WinkelBert E. J. E. G. Bast REVIEW Pages: 121 - 123
Targeting tumor cell destruction with CD64-directed bispecific fusion proteins Robert F. GrazianoJoel GoldsteinYashwant M. Deo ORIGINAL ARTICLE Pages: 124 - 127
FcγRI blockade and modulation for immunotherapy P. K. WallaceTibor KelerMichael W. Fanger ORIGINAL ARTICLE Pages: 137 - 141
Activated neutrophils as effector cells for bispecific antibodies T. ValeriusDieter WürfleinMartin Gramatzki ORIGINAL ARTICLE Pages: 142 - 145
Increased potency of Fc-receptor-targeted antigens P. M. GuyreRobert F. GrazianoAlexandra L. Howell ORIGINAL ARTICLE Pages: 146 - 148
Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation T. J. WickhamDorian HaskardImre Kovesdi ORIGINAL ARTICLE Pages: 149 - 151
Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor R. P. TaylorAlessandra NardinWilliam M. Sutherland ORIGINAL ARTICLE Pages: 152 - 155
Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein Bernhard GerstmayerMichael HoffmannW. Wels ORIGINAL ARTICLE Pages: 156 - 158
Bispecific-Ab-based immunoassay of thyroid-stimulating hormone Kuniyo Inouye ORIGINAL ARTICLE Pages: 159 - 161
Bispecific antibody treatment of murine B cell lymphoma J. De JongeCarlo HeirmanK. Thielemens ORIGINAL ARTICLE Pages: 162 - 165
Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRI×murine MHC class II bispecific antibody Ingmar A. F. M. HeijnenMartin J. GlennieJ. G. J. van de Winkel ORIGINAL ARTICLE Pages: 166 - 170
Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome Jamie HoneychurchAndrew CruiseM. J. Glennie ORIGINAL ARTICLE Pages: 171 - 173
T-cell activation induced by anti-CD3 × anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand James E. WooldridgeChris E. DahleGeorge J. Weiner ORIGINAL ARTICLE Pages: 174 - 179
T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: An effective in vivo antitumor strategy Lewis E. Porter Heidi NelsonAndrei I. Chapoval ORIGINAL ARTICLE Pages: 180 - 183
Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody Cristoph RennerFrank HartmannM. Pfreundschuh ORIGINAL ARTICLE Pages: 184 - 186
Approaches to implement bispecific antibody treatment of ovarian carcinoma S. CanevariDelia MezzanzanicaMaria I. Colnaghi ORIGINAL ARTICLE Pages: 187 - 189
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins Louis M. WeinerR. Katherine AlpaughMargaret von Mehren ORIGINAL ARTICLE Pages: 190 - 192
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer P. KuferM. MackG. Riethmüller ORIGINAL ARTICLE Pages: 193 - 197
CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma Oliver Manzke Sandra TitzerH. Bohlen ORIGINAL ARTICLE Pages: 198 - 202
Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1 B. J. KroesenJ. NiekenL. de Leij ORIGINAL ARTICLE Pages: 203 - 206
Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer H. H. van Ojik R. ReppJan G. J. van de Winkel ORIGINAL ARTICLE Pages: 207 - 209
Clinical experience with CD64-directed immunotherapy. An overview Randall T. Curnow ORIGINAL ARTICLE Pages: 210 - 215
